Safety and Efficacy of Campath in Nonmyeloablative Transplantation
Lymphoma, Leukemia
About this trial
This is an interventional treatment trial for Lymphoma focused on measuring Lymphoma, Leukemia, Campath-1 H, Campath, Alemtuzumab, Fludarabine, Fludarabine Phosphate, Fludara, Cyclophosphamide, Cytoxan, Neosar, Rituxan, Rituximab
Eligibility Criteria
Inclusion Criteria: Up to 70 years of age (physiological). Any histological subtype of lymphoid malignancies (those with CD20 negative disease will not receive Rituximab). Patients in relapse with a partial remission or stable disease. Patients who failed a prior autologous transplant are also eligible. Patients must have a matched unrelated donor and no human leukocyte antigen (HLA) identical sibling is available. Point scale (PS)<2. Patients are included even if they were previously exposed to Campath or Rituximab. Exclusion Criteria: Past history of anaphylaxis following exposure to rat- or mouse-derived COR-grafted humanized monoclonal antibodies. Less than 4 weeks since prior chemotherapy counted from 1st day of treatment regimen. Pregnancy or lactation. HIV or HTLV-I positively. Serum creatinine >1.6mg/dl or serum bilirubin >1.5mg/dl unless due to tumor. Pulmonary function tests (PFTs) -OLCO<50%, cardiac EF <50% of predicted levels. Patient with severe concomitant medical or psychiatric illness.
Sites / Locations
- U.T.M.D. Anderson Cancer Center
Arms of the Study
Arm 1
Experimental
Campath in Nonmyeloablative Transplantation
Campath-1 H Starting Dose of 15 mg by vein daily, 3 days in a row + Fludarabine 30 mg/m2 by vein daily, 3 days in a row + Cyclophosphamide 1 gm/m2 by vein daily, 3 days in a row + Rituximab 375 mg/m2 by vein, given 8 days before transplant then weekly for 4 total doses.